STOCKS
Micron’s Korea Gut Check |
|
Micron, the memory-chip maker supplying AI data centers, plunged 13.2% Tuesday after South Korea’s regulators issued a warning on leveraged tech ETFs. The news triggered a 10% KOSPI crash, and a 20-minute market-wide halt. Samsung and SK Hynix, which represent more than half the index, each sank over 12%. The forced unwind crossed the Pacific, knocking Micron 13%, SanDisk 14%, Western Digital 8%, Seagate 5%, and the Roundhill Memory ETF 14%. |
The RIP: $MU ( ▼ 13.18% ) fell 13.18%, then gained 2.49% after hours. For tomorrows report, consensus calls for $20.39 adjusted EPS on $35.5B revenue, with DRAM at $27.5B, NAND at $7.7B, and adjusted gross margin at 81.83%. |
Bank of America still raised its price target 58% Tuesday, from $950 to $1,500, arguing AI demand visibility extends into 2028. Micron also signed a memory, storage, and investment agreement with Anthropic, but Wednesday’s guidance must prove Korea’s collapse was a leveraged positioning shock, not an early warning that the memory cycle has peaked. |
Stocks sentiment is neutral with low message volume across roughly 202K watchers. |
@MBSB said: “$MU forward guidance is what matters here” (post) @whatevermyguy said: “$MU anyone else read the SK Hynix news and actually think it’s bullish for Micron?” (post) @Liuyilong said: “$MU Back to $900 after earnings tomorrow... demand is down” (post)
|
Make your $MU case: cycle or rerating → |
Nike Limps Into Earnings |
Nike, the sneaker and athletic-apparel giant, is also sliding toward its fiscal fourth-quarter report after a wave of analyst downgrades, even as the company tried to steady nerves Tuesday by pre-announcing in-line guidance and naming a new finance chief. |
The RIP: $NKE ( ▼ 1.88% ) closed down 1.9% at $42.38, near its 52-week low of $41 and far below the $78 high, then ticked up 1.2% to $42.89 after hours. Nike pre-announced fiscal Q4 results "generally in line" with prior guidance and named David Denton CFO, effective Aug. 17. |
@bertier31 said: "$NKE if you are doing anything other than holding or buying right now, you are wrong. Nike's margins are about to expand wildly." (post) @Advancedo said: "$NKE crooks Goldman and Evercore loaded cheap shares. See you at +50 after ER." (post)
|
Make your $NKE case: bottom or value trap → |
Pharma Hides From Tech |
Merck jumped 3.6% and Johnson & Johnson gained 3.4% Tuesday as investors rotated toward defensive drugmakers during the tech rout. Merck brought the fresher catalyst: its experimental ulcerative colitis treatment tulisokibart met the primary and key secondary endpoints in a Phase 3 study. |
The RIP: $MRK ( ▲ 3.57% ) closed at $119.60, up 3.57%. $JNJ finished at $239.08, up 3.37%. Tulisokibart strengthens Merck’s effort to build growth beyond Keytruda, although Roche’s competing TL1A program keeps the commercial race open. |
Both Stocks streams are neutral. Merck has normal message volume, while Johnson & Johnson has high message volume. Make your $MRK case: rotation or pipeline rerating → |
